Ramipril

Basic Information


CAS ID: 87333-19-5
Molecular Formula: C23H32N2O5
Molecular Weight: 416.5 g/mol
Monoisotopic Mass: 416.2311 g/mol
Class: Small Molecule
Natural Product: No
Other Names: HOE 498 | RAMIPRIL | ALTACE | RANACE | TRITACE | LOPACE
Analysis: Drug repositioning mechanism analysis

O O NH O N O OH


Compound Structure and Identifier


InChI: InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1 See All
InChI Key: HDACQVRGBOVJII-JBDAPHQKSA-N
Smiles: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O See All
Molfile: Download


Related Target


Target ID Name Interaction
T0213 Angiotensin-converting enzyme inhibitor

Related Fibrosis Property


Reference Record 1

PubMed ID 17094052 Target ID T0213
Uniprot ID Angiotensin-converting enzyme Name Angiotensin-converting enzyme
Model rat Fibrosis Disease Cardiac fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism

Reference Record 2

PubMed ID 28438648 Target ID T0213
Uniprot ID Angiotensin-converting enzyme Name Angiotensin-converting enzyme
Model rat Fibrosis Disease Renal fibrosis
Process I attenue inflammation
Process II
Process III prevenet collagen deposition
Mechanism

Trial Record 1

ClinicalTrial ID NCT02842424 Disease Muscle fibrosis
Phase Phase 4 Status Recruiting
First Received July 22, 2016 Last Verified October 31, 2018
Sponsor University of Nebraska

Trial Record 2

ClinicalTrial ID NCT01485978 Disease Liver fibrosis
Phase Phase 3 Status Active, not recruiting
First Received December 6, 2011 Last Verified October 25, 2017
Sponsor Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Related Link


PubChem: 6992028
ChEMBL: CHEMBL1168